GleamWall
中文EN

TGTX TG THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1001316 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY68.8%
TTM net income YoY-76.3%
TTM EPS YoY-75.8%
Revenue 3-yr CAGR67.9%
Net income 3-yr CAGR—

Margins

Gross margin82.7%
Operating margin21.5%
Net margin11.8%
FCF margin9.5%
EBITDA margin21.5%

Returns

ROE18.0%
ROA8.1%
ROIC (approx.)16.4%
Asset turnover0.69x

Leverage & solvency

Liabilities / assets64.1%
Debt / equity1.30x
Current ratio4.50x
Interest coverage4.14x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio1.5%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$259.94M$240.34M$204.92M$192.57M$161.71M$141.15M$120.86M$108.19M
Cost of revenue$42.08M$41.19M$33.51M$38.14M$28.09M$18.94M$15.54M$15.40M
Gross profit$217.86M$199.14M$171.41M$154.43M$133.62M$122.21M$105.31M$92.79M
R&D expense$51.29M$95.34M$48.40M$41.19M$40.88M$31.78M$46.36M$23.87M
SG&A expense$80.67M$82.13M$88.22M$62.74M$63.37M$55.59M$50.33M$38.96M
Operating income$85.90M$21.67M$34.80M$50.49M$29.36M$34.84M$8.62M$29.95M
Interest expense$15.82M$16.57M$7.67M$6.53M$6.72M$6.72M$6.76M$7.06M
Pretax income$73.86M$10.23M$20.36M$45.09M$25.91M$30.92M$5.47M$25.45M
Income tax$18.40M$2.45M$586,000$22.06M-$364.99M$2.73M$408,000$2.12M
Net income$55.46M$7.78M$19.78M$23.04M$390.89M$28.19M$5.06M$23.33M
EBITDA$85.97M$21.73M$34.83M$50.52M$29.38M$34.86M$8.63M$29.96M
EPS (basic)0.390.050.14—2.690.190.03—
EPS (diluted)0.350.050.12—2.430.170.03—
Weighted avg. shares (diluted)155.93M157.28M160.06M—161.00M162.56M162.77M—
Balance sheet
Cash & equivalents$429.38M$482.57M$442.21M$79.15M$74.08M$129.13M$132.14M$179.89M
Short-term investments$75.30M$69.67M$72.22M$62.82M$57.50M$122.74M$144.10M$131.11M
Receivables$416.82M$401.56M$392.05M$305.63M$265.38M$231.52M$190.12M$129.19M
Inventory$194.32M$147.97M$129.03M$125.59M$146.95M$155.20M$157.76M$110.46M
Current assets$1.17B$1.15B$1.09B$630.76M$599.76M$663.96M$644.51M$566.36M
Total assets$1.59B$1.64B$1.53B$1.06B$1.03B$702.61M$656.69M$577.69M
Current liabilities$260.53M$268.49M$187.11M$153.76M$156.81M$171.89M$160.21M$90.68M
Long-term debt$745.63M$745.39M$745.14M$245.65M$245.34M$245.04M$244.73M$244.43M
Total debt$745.63M$745.39M$745.14M$245.65M$245.34M$245.04M$244.73M$244.43M
Total liabilities$1.02B$1.04B$945.71M$415.23M$417.81M$426.18M$419.40M$355.33M
Shareholders' equity$572.13M$604.08M$583.13M$648.02M$607.22M$276.43M$237.29M$222.36M
Net debt$316.26M$262.81M$302.93M$166.50M$171.26M$115.91M$112.59M$64.53M
Shares outstanding151.16M153.08M153.09M155.31M155.21M158.03M158.17M155.84M
Cash flow statement
Operating cash flow$45.23M$39.26M-$17.89M$19.66M-$23.15M$7.44M-$28.71M-$25.64M
Capital expenditure$282,000$293,000$51,000$67,000$80,000$42,000$25,000$21,000
Free cash flow$44.95M$38.97M-$17.95M$19.59M-$23.23M$7.39M-$28.74M-$25.66M
Investing cash flow$1.33M$1.03M-$9.86M-$15.64M$46.36M-$3.99M-$12.93M$15.79M
Financing cash flow-$99.75M$85,000$390.83M$1.06M-$78.24M-$6.44M-$6.10M-$6.07M
Depreciation & amortization$73,000$53,000$32,000$21,000$17,000$13,000$8,000$9,000
Stock-based compensation$24.70M$27.88M$19.95M$15.65M$17.69M$16.40M$14.97M$11.95M

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.